Louis Bont
Biographic Data
| ID | 9021075 |
|---|---|
| NAME | Louis Bont |
| GIVEN NAMES | Louis |
| FAMILY NAME | Bont |
| SIGNATURE | BONT L |
| AFFILIATIONS | University Medical Center Utrecht |
| ORCID | 0000-0003-3099-4475 |
| VERIFIED | Yes |
| TOTAL WORKS | 13 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 13 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2015 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Diagnostic accuracy of a molecular-based point-of-care test for rapid detection of respiratory syncytial virus in children admitted to high-dependency care in Nepal
Background: Rapid respiratory syncytial virus (RSV) diagnostics are largely unavailable in low-resource settings. We compared the diagnostic accuracy of a molecular-based point-of-care test (POCT) with standard reverse transcription polymerase chain reaction (RT-PCR) in children admitted to high-dependency care. Methods: We analysed data from a larger study (RSV GOLD - ICU Network study) in two Nepali tertiary hospitals over two respiratory seaso…
Antibiotic use in respiratory syncytial virus-positive children under two years
Introduction Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in children, often leading to hospitalization in infants and vulnerable children. In low-resource settings where routine RSV diagnostics are unavailable, the overlap between clinical symptoms of RSV and those of bacterial pneumonia leads to unnecessary antibiotic use and contributes to the development of antimicrobial resistance. We conducted thi…
Proof-of-principle of a technology transfer of a dried blood virus neutralisation assay to a Gavi-eligible country
BACKGROUND: Global health clinical research is commonly led by high-income countries (HICs) as low- and middle-income countries (LMICs) face barriers to participate, including lack of financial and human capacity and lack of research environment. Respiratory syncytial virus (RSV) vaccine development is also led by HICs, while LMICs carry the burden of life-threatening disease. Representative trials and research capacity strengthening in LMICs are…
How well do disease-specific studies and WHO-CHOICE cost estimates align? Example of estimating cost per episode of diarrhoea and respiratory syncytial virus in 128 low-income and middle-income countr…
OBJECTIVE: Non-disease-specific WHO-CHOICE (CHOosing Interventions that are Cost-Effective) unit costs are often used in cost and cost-effectiveness studies in the absence of country-specific data. This study aims to compare reported country-specific disease costs and the corresponding WHO-CHOICE estimates, using generically defined 'diarrhoea' (including rotavirus diarrhoea) and pathogen-specific 'respiratory syncytial virus (RSV)' disease in ch…
Estimating the economic burden of respiratory syncytial virus infection among children <2 years old seeking care in North-West Nigeria
Background: Respiratory syncytial virus (RSV) disease burden is highest in low- and middle-income countries; yet data for costs of RSV-related illness in these settings are scarce. We estimated RSV costs of illness to inform decision-making for RSV preventive strategies in Nigeria. Methods: This prospective study assessed the costs of care per episode of (severe) acute respiratory infection during one RSV season (April to November 2023). Children…
Cost-effectiveness of introducing a maternal vaccine or long-acting monoclonal antibody to prevent infant respiratory syncytial virus disease in Nepal
Background: The World Health Organization recommends two passive immunisation strategies to prevent respiratory syncytial virus (RSV) disease in young infants. Both are being introduced in high-income settings, but their affordability and cost-effectiveness have not been evaluated in many low- and middle-income countries. Preliminary estimates of cost-effectiveness are needed to guide immunisation policy and planning in Nepal. Methods: We estimat…
Estimating the economic burden of respiratory syncytial virus infection among children <2 years old receiving care in Maputo, Mozambique
Background: Data on costs of respiratory syncytial virus (RSV) in low- and lower-middle-income countries are urgently needed to inform the introduction of recently developed vaccines. We estimated the costs of lower respiratory tract infections associated with RSV infection in Mozambique. Methods: We conducted a prospective cohort study to assess household and societal costs of RSV infection in children <2 years old who sought care in a referral …
Assessing the cost of illness of RSV and non-RSV acute respiratory infections in Nepali children
Background: Low- and middle-income countries (LMICs) bear the greatest burden of the global respiratory syncytial virus (RSV) morbidity and mortality, but lack cost data to evaluate the health-economic impact of RSV burden on families, the healthcare system, and society. This prospective observational study was performed by the RSV GOLD III - Health Economic Research Group and estimated the costs associated with RSV illness in Nepal. Methods: We …
Respiratory syncytial virus
Human respiratory syncytial virus (RSV), a leading cause of serious respiratory illness, can affect individuals of all ages, especially children below two years of age and adults 60 years of age and above, as well as individuals with chronic comorbidities, such as chronic pulmonary or cardiovascular conditions, and immunocompromised individuals [1,2]. In adults, clinical outcomes [...]
Are maternal vaccines effective and safe for mothers and infants? A systematic review and meta-analysis of randomised controlled trials
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019
BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory infection in young children. We previously estimated that in 2015, 33·1 million episodes of RSV-associated acute lower respiratory infection occurred in children aged 0-60 months, resulting in a total of 118 200 deaths worldwide. Since then, several community surveillance studies have been done to obtain a more precise estimation of RSV associated co…
The burden of respiratory syncytial virus (RSV) associated acute lower respiratory infections in children with Down syndrome
Respiratory syncytial virus (RSV) disease – new data needed to guide future policy
RSV is the main cause of childhood lower respiratory infections, globally, an important cause of childhood wheeze and may be responsible for a substantial burden of disease in the very elderly and in adults with chronic medical problems, such as COPD. It is thus responsible for substantial healthcare and social costs. There are currently many companies and academic groups developing and testing candidate vaccines and there is an expectation that …
No prominent works on this page.
Respiratory syncytial virus (RSV) disease – new data needed to guide future policy
RSV is the main cause of childhood lower respiratory infections, globally, an important cause of childhood wheeze and may be responsible for a substantial burden of disease in the very elderly and in adults with chronic medical problems, such as COPD. It is thus responsible for substantial healthcare and social costs. There are currently many companies and academic groups developing and testing candidate vaccines and there is an expectation that …
The burden of respiratory syncytial virus (RSV) associated acute lower respiratory infections in children with Down syndrome
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019
BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory infection in young children. We previously estimated that in 2015, 33·1 million episodes of RSV-associated acute lower respiratory infection occurred in children aged 0-60 months, resulting in a total of 118 200 deaths worldwide. Since then, several community surveillance studies have been done to obtain a more precise estimation of RSV associated co…
Are maternal vaccines effective and safe for mothers and infants? A systematic review and meta-analysis of randomised controlled trials
Respiratory syncytial virus
Human respiratory syncytial virus (RSV), a leading cause of serious respiratory illness, can affect individuals of all ages, especially children below two years of age and adults 60 years of age and above, as well as individuals with chronic comorbidities, such as chronic pulmonary or cardiovascular conditions, and immunocompromised individuals [1,2]. In adults, clinical outcomes [...]
Proof-of-principle of a technology transfer of a dried blood virus neutralisation assay to a Gavi-eligible country
BACKGROUND: Global health clinical research is commonly led by high-income countries (HICs) as low- and middle-income countries (LMICs) face barriers to participate, including lack of financial and human capacity and lack of research environment. Respiratory syncytial virus (RSV) vaccine development is also led by HICs, while LMICs carry the burden of life-threatening disease. Representative trials and research capacity strengthening in LMICs are…
How well do disease-specific studies and WHO-CHOICE cost estimates align? Example of estimating cost per episode of diarrhoea and respiratory syncytial virus in 128 low-income and middle-income countr…
OBJECTIVE: Non-disease-specific WHO-CHOICE (CHOosing Interventions that are Cost-Effective) unit costs are often used in cost and cost-effectiveness studies in the absence of country-specific data. This study aims to compare reported country-specific disease costs and the corresponding WHO-CHOICE estimates, using generically defined 'diarrhoea' (including rotavirus diarrhoea) and pathogen-specific 'respiratory syncytial virus (RSV)' disease in ch…
Estimating the economic burden of respiratory syncytial virus infection among children <2 years old seeking care in North-West Nigeria
Background: Respiratory syncytial virus (RSV) disease burden is highest in low- and middle-income countries; yet data for costs of RSV-related illness in these settings are scarce. We estimated RSV costs of illness to inform decision-making for RSV preventive strategies in Nigeria. Methods: This prospective study assessed the costs of care per episode of (severe) acute respiratory infection during one RSV season (April to November 2023). Children…
Cost-effectiveness of introducing a maternal vaccine or long-acting monoclonal antibody to prevent infant respiratory syncytial virus disease in Nepal
Background: The World Health Organization recommends two passive immunisation strategies to prevent respiratory syncytial virus (RSV) disease in young infants. Both are being introduced in high-income settings, but their affordability and cost-effectiveness have not been evaluated in many low- and middle-income countries. Preliminary estimates of cost-effectiveness are needed to guide immunisation policy and planning in Nepal. Methods: We estimat…
Estimating the economic burden of respiratory syncytial virus infection among children <2 years old receiving care in Maputo, Mozambique
Background: Data on costs of respiratory syncytial virus (RSV) in low- and lower-middle-income countries are urgently needed to inform the introduction of recently developed vaccines. We estimated the costs of lower respiratory tract infections associated with RSV infection in Mozambique. Methods: We conducted a prospective cohort study to assess household and societal costs of RSV infection in children <2 years old who sought care in a referral …
Assessing the cost of illness of RSV and non-RSV acute respiratory infections in Nepali children
Background: Low- and middle-income countries (LMICs) bear the greatest burden of the global respiratory syncytial virus (RSV) morbidity and mortality, but lack cost data to evaluate the health-economic impact of RSV burden on families, the healthcare system, and society. This prospective observational study was performed by the RSV GOLD III - Health Economic Research Group and estimated the costs associated with RSV illness in Nepal. Methods: We …
Diagnostic accuracy of a molecular-based point-of-care test for rapid detection of respiratory syncytial virus in children admitted to high-dependency care in Nepal
Background: Rapid respiratory syncytial virus (RSV) diagnostics are largely unavailable in low-resource settings. We compared the diagnostic accuracy of a molecular-based point-of-care test (POCT) with standard reverse transcription polymerase chain reaction (RT-PCR) in children admitted to high-dependency care. Methods: We analysed data from a larger study (RSV GOLD - ICU Network study) in two Nepali tertiary hospitals over two respiratory seaso…
Antibiotic use in respiratory syncytial virus-positive children under two years
Introduction Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in children, often leading to hospitalization in infants and vulnerable children. In low-resource settings where routine RSV diagnostics are unavailable, the overlap between clinical symptoms of RSV and those of bacterial pneumonia leads to unnecessary antibiotic use and contributes to the development of antimicrobial resistance. We conducted thi…
Respiratory viral infections research (11 works) · Medicine (7 works) · Respiratory system (7 works) · Virus (7 works) · Disease (4 works) · Environmental health (4 works) · Internal Medicine (4 works) · Pediatrics (4 works) · Virology and Viral Diseases (4 works) · Intensive care medicine (3 works)